GTx inserts another drug into FDA

Memphis-based and NASDAQ-listed GTx, Inc., this week announced its submission of a New Drug Application to the FDA, covering an oral selective estrogen receptor modulator (SERM) for prevention of bone fractures in men with prostate cancer and undergoing androgen-hormone deprivation therapy. The GTx release is here. [Update: Jan. 5 - Memphis Daily News reported that a lawsuit involving GTx, the UT Foundation and Merck has been settled. GTx's SEC filing is here.)